Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TYR | P14679 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3999963 | 0.80 | ATM (0.48) | ALDH1A1CA2POLBTYRSMN1; SMN2 | |
| SCHEMBL2127105 | 0.77 | VCAM1 (0.36) | SMN1; SMN2VCAM1 | |
| SCHEMBL295975 | 0.77 | KDM4E (0.40) | ALDH1A1CA2POLBTYRSMN1; SMN2 | |
| SCHEMBL19770698 | 0.76 | ALDH1A1 (0.41) | ALDH1A1CA2POLBTYRSMN1; SMN2 | |
| SCHEMBL2141477 | 0.74 | CYP1A2 (0.36) | ALDH1A1CA2POLBTYRSMN1; SMN2 | |
| SCHEMBL294972 | 0.73 | LMNA (0.50) | — | |
| SCHEMBL8407409 | 0.73 | ALDH1A1 (0.48) | ALDH1A1CA2POLBTYRSMN1; SMN2 | |
| SCHEMBL27592032 | 0.73 | ATM (0.49) | ALDH1A1ATM | |
| SCHEMBL2126900 | 0.72 | ALDH1A1 (0.35) | ALDH1A1CA2POLBTYRSMN1; SMN2 | |
| SCHEMBL2129348 | 0.72 | VCAM1 (0.36) | SMN1; SMN2VCAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1683783-B1 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL CO (JP) | 2012-03-14 | — | — | EP | disclosed |
| EP-1683782-B1 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL CO (JP) | 2012-03-14 | — | — | EP | disclosed |
| EP-1120402-B1 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL CO (JP) | 2008-06-25 | — | — | EP | disclosed |
| EP-1683782-A2 | Chiral copper complex and production processes thereof and using the same | Sumitomo Chemical Company, Limited (JP) | 2006-07-26 | — | — | EP | disclosed |
| EP-1683783-A2 | Chiral copper complex and production processes thereof and using the same | Sumitomo Chemical Company, Limited (JP) | 2006-07-26 | — | — | EP | disclosed |
| US-20050090684-A1 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL CO., LTD. | 2005-04-28 | — | — | US | disclosed |
| US-6670500-B2 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-12-30 | — | — | US | disclosed |
| US-6469198-B2 | OBTAINED BY CONTACTING N-SALICYLIDENEAMINOALCOHOL WITH MONO OR DIVALENT COPPER COMPOUND; FORMATION OF OPTICALLY ACTIVE CYCLOPROPANE-CARBOXYLIC ESTER FROM PROCHIRAL OLEFIN AND DIAZOACETIC ACID ESTER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-10-22 | — | — | US | disclosed |
| US-20020004618-A1 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-01-10 | — | — | US | disclosed |
| US-20010037036-A1 | Chiral copper complex catalyst composition and asymmetric production process using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-11-01 | — | — | US | disclosed |
| EP-1120402-A2 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-08-01 | — | — | EP | disclosed |
| EP-1120401-A2 | Chiral copper complex catalyst composition and asymmetric production process using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090684-A1 | Chiral copper complex and production processes thereof and using the same | SOD1, CYP1A1, NFXL1 | ALDH1A1 16/4885CA2 552/4885POLB 1250/4885 |
| US-20010037036-A1 | Chiral copper complex catalyst composition and asymmetric production process using the same | AP1M1, UBA3, AP1S1 | ALDH1A1 254/4885CA2 630/4885POLB 544/4885 |
| US-20020004618-A1 | Chiral copper complex and production processes thereof and using the same | SOD1, XDH, NFXL1 | ALDH1A1 19/4885CA2 516/4885POLB 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.